Compare AstraZeneca plc (AZN) vs Advanced Drainage Systems Inc (WMS) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

WMS trades at $147.62, down 1.89% on the day, with a bullish technical signal and strong fundamentals including a 24.02% ROE and consistent earnings beats. Recent news includes a dividend increase and investor day, while cash flow dipped in 2025 but is projected to recover. The stock shows robust profitability with a 13.98% net margin and trades below the consensus price target of $184.43.

Outlook is positive with analyst support and operational strength, but risks include a high P/E of 27.09 and mixed sentiment from recent Strong Sell ratings. Upside potential exists if earnings momentum continues, though investors should monitor debt levels and competitive pressures in the water management sector.